Literature DB >> 7808790

p53 expression in human renal cell carcinoma: an immunohistochemical study and a literature outline of the cytogenetic characterization.

R M Tomasino1, V Morello, V Tralongo, C Nagar, R Nuara, E Daniele, M Curti, F Orestano.   

Abstract

In this study both the incidence and pattern of p53 over-expression in various histological subtypes of a series of 36 cases of renal cell Grawitz carcinoma, partially studied in a previous paper, were analyzed. This series consisted of these histologic subtypes: clear cell non papillary (18 cases), clear cell papillary (2 cases), granular cell (5 cases), mixed (clear and granular cell) (9 cases) and spindle cell (2 cases). At present, our aim was, firstly, to see which were the best technical conditions for detection of p53 in the available paraffin-embedded tumor specimens, using several antibodies, specific for various epitopes; secondly, to investigate if some relation might exist between this expression and the histological features of these tumors. Twenty-five per cent (9/36 cases) resulted p53 immunoreactive, the highest percentage being represented in the papillary clear and granular cell carcinomas; low expression was detected in 11 cases (30%) and no reactivity in 16 cases (44%). Neither technical or dilution modifications proved to transform these latter results; however, detection was maximal using the CM-1 polyclonal rabbit antiserum. Thus, in RCC, expression of p53, analyzed in the light of the cytogenetic characterization through a literature review, resulted at low frequency. This finding means that mutation of the p53 gene are not frequent in the neoplastic transformation in RCC. Nevertheless, in spite of the small number of cases and of the short follow-up period of this study, detection of p53 positivity in tumors with either high grade and stage or high proliferative activity could suggest that p53 mutations lead to tumors of a more aggressive type.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7808790

Source DB:  PubMed          Journal:  Pathologica        ISSN: 0031-2983


  6 in total

Review 1.  Choosing The Right Animal Model for Renal Cancer Research.

Authors:  Paweł Sobczuk; Anna Brodziak; Mohammed Imran Khan; Stuti Chhabra; Michał Fiedorowicz; Marlena Wełniak-Kamińska; Kamil Synoradzki; Ewa Bartnik; Agnieszka Cudnoch-Jędrzejewska; Anna M Czarnecka
Journal:  Transl Oncol       Date:  2020-02-22       Impact factor: 4.243

2.  UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer.

Authors:  M Unoki; J D Kelly; D E Neal; B A J Ponder; Y Nakamura; R Hamamoto
Journal:  Br J Cancer       Date:  2009-06-02       Impact factor: 7.640

3.  Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells.

Authors:  Andrew M Roberts; Ian R Watson; Andrew J Evans; David A Foster; Meredith S Irwin; Michael Ohh
Journal:  Cancer Res       Date:  2009-11-17       Impact factor: 12.701

Review 4.  Two sides to every story: the HIF-dependent and HIF-independent functions of pVHL.

Authors:  Mingqing Li; William Y Kim
Journal:  J Cell Mol Med       Date:  2011-02       Impact factor: 5.310

5.  Low expression of phosphatase and tensin homolog in clear‑cell renal cell carcinoma contributes to chemoresistance through activating the Akt/HDM2 signaling pathway.

Authors:  Jun Chen; He Zhu; Yan Zhang; Man-Hua Cui; Li-Ying Han; Zhan-Hui Jia; Ling Wang; Hong Teng; Li-Ning Miao
Journal:  Mol Med Rep       Date:  2015-05-07       Impact factor: 2.952

6.  VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma.

Authors:  Caroline Fanja Razafinjatovo; Daniel Stiehl; Eva Deininger; Markus Rechsteiner; Holger Moch; Peter Schraml
Journal:  Oncotarget       Date:  2017-02-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.